Conference abstract
ArticlePublished 30 Jan 2024
Ups and Downs in MS Therapeutics
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Over the past three decades, there has been a remarkable surge in the approval of drugs for treating Multiple Sclerosis (MS), with the number now exceeding 15 options, including various dosages and generics. However, while these treatments have primarily targeted the inflammatory activity underlying relapses, the progressive aspects of MS, characterized by a gradual worsening of disability without relapses, remain inadequately addressed. Siponimod and Ocrelizumab have emerged as crucial drugs approved for treating progressive forms of MS, particularly primary progressive and secondary progressive MS. Despite their benefits for patients experiencing clinical relapses or displaying disease activity in MRI scans, their use is limited to those with active disease as per regulators in the US and Europe. This leaves a significant treatment gap for patients with progressive MS lacking active disease. Addressing this gap, Jeremy Chataway and colleagues conducted a multi-arm phase 2b trial named the Multiple Sclerosis Secondary Progressive Multi-Arm Randomization Trial (MS-SMART), as reported in The Lancet Neurology. The trial selected three experimental drugs—amiloride, fluoxetine, and riluzole—based on an extensive systematic review of 532 potential treatment options. These drugs target axonal pathology and neuroprotection and boast a robust safety profile in humans, rendering them suitable candidates for testing in progressive MS. This study underscores the urgent need for more effective treatments to fill the existing gap in care for patients with progressive MS, particularly those without active disease
Subjects
Neuroscience & NeurologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Opinion · 30 Jul 2023
Fluctuations in Multiple Sclerosis Therapeutics: Abundance or Scarcity
Conference abstract · 2018
The bioenergetic role for Myelin suggest new approach to therapeutic of Multiple Sclerosis
Conference abstract · 2017
HLA-immunogenetics in multiple sclerosis: On clinical applications and personalized therapeutics
Conference abstract · 18 Jul 2016
T-VDMS- Therapeutic Potential of Vitamin D3 as an add on to Interferon Beta in Patients with Multiple Sclerosis in Sulaimaniyah, KRG-Iraq
More from this journal
The newest in Journal of Multiple Sclerosis.
Article · 7 Apr 2026
A Link between Smoking and Age at Onset in Multiple Sclerosis
Article · 12 Feb 2026
Demyelination: Understanding the Disruption of Nerve Function
Article · 12 Feb 2026
Brain Tumors: Insights into Diagnosis, Management, and Future Perspectives
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Multiple Sclerosis
- SubjectNeuroscience & Neurology
- BylineArticles whose byline prints “Abdul Aftab”
- BylineArticles whose byline prints “Pankaj Majlumdar”

